MSD

Pembrolizumab /7684A

Biodrugs/ Drugs
Cancer
Study of MK-7684A plus Chemotherapy versus Pembrolizumab plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer
3Phase III in Spain, 2Phase II, 1Phase I